GMAB vs HSIC: fair value comparison
Genmab A/S and Henry Schein, Inc. · Updated 2026-09-12
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, HSIC currently sits closer to the top of our discount ranking. GMAB carries the stronger quality grade.
| GMAB | HSIC | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $33.29 | $88.36 |
| 12-month range | $25.45–$33.29 | $63.20–$88.52 |
| Sector rank | #72 of 113 Healthcare | #71 of 113 Healthcare |
| Quality grade | D | F |
| Leverage | Moderate | Moderate |
| Margin trend | Contracting | Stable |
| Revenue growth | Declining | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Uptrend |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: GMAB fair value analysis · HSIC fair value analysis